A citation-based method for searching scientific literature

Thomas Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode, Bertrand Cariou, Kelly L Close, Paresh Dandona, Sanjoy Dutta, Ele Ferrannini, Spiros Fourlanos, George Grunberger, Simon R Heller, Robert R Henry, Martin J Kurian, Jake A Kushner, Tal Oron, Christopher G Parkin, Thomas R Pieber, Helena W Rodbard, Desmond Schatz, Jay S Skyler, William V Tamborlane, Koutaro Yokote, Moshe Phillip. Diabetes Care 2019
Times Cited: 89







List of co-cited articles
514 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
97
40

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya,[...]. Diabetes Care 2018
102
35

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
178
35

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
141
33

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
78
35

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
31

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
88
29

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters,[...]. Diabetes Care 2018
76
31


Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
25

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
24

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Anne L Peters, Elizabeth O Buschur, John B Buse, Pejman Cohan, Jamie C Diner, Irl B Hirsch. Diabetes Care 2015
388
22

State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018.
Nicole C Foster, Roy W Beck, Kellee M Miller, Mark A Clements, Michael R Rickels, Linda A DiMeglio, David M Maahs, William V Tamborlane, Richard Bergenstal, Elizabeth Smith,[...]. Diabetes Technol Ther 2019
382
20


Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.
Kellee M Miller, Nicole C Foster, Roy W Beck, Richard M Bergenstal, Stephanie N DuBose, Linda A DiMeglio, David M Maahs, William V Tamborlane. Diabetes Care 2015
700
16



SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, Kyungah Im, Erica L Goodrich, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Remo H M Furtado,[...]. Lancet 2019
753
14

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
14

SGLT2 Inhibitors May Predispose to Ketoacidosis.
Simeon I Taylor, Jenny E Blau, Kristina I Rother. J Clin Endocrinol Metab 2015
239
13

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
93
13

Hyperglycemic crises in adult patients with diabetes.
Abbas E Kitabchi, Guillermo E Umpierrez, John M Miles, Joseph N Fisher. Diabetes Care 2009
661
13

Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
T R Pieber, S Famulla, J Eilbracht, J Cescutti, N Soleymanlou, O E Johansen, H J Woerle, U C Broedl, S Kaspers. Diabetes Obes Metab 2015
97
13

Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Thomas Danne, Bertrand Cariou, John B Buse, Satish K Garg, Julio Rosenstock, Phillip Banks, Jake A Kushner, Darren K McGuire, Anne L Peters, Sangeeta Sawhney,[...]. Diabetes Care 2019
27
40


Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
644
11

Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry.
Ruth S Weinstock, Dongyuan Xing, David M Maahs, Aaron Michels, Michael R Rickels, Anne L Peters, Richard M Bergenstal, Breanne Harris, Stephanie N Dubose, Kellee M Miller,[...]. J Clin Endocrinol Metab 2013
175
11

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
John R Petrie, Nishi Chaturvedi, Ian Ford, Martijn C G J Brouwers, Nicola Greenlaw, Therese Tillin, Irene Hramiak, Alun D Hughes, Alicia J Jenkins, Barbara E K Klein,[...]. Lancet Diabetes Endocrinol 2017
121
11

Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
145
11


Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality - United States, 2000-2014.
Stephen R Benoit, Yan Zhang, Linda S Geiss, Edward W Gregg, Ann Albright. MMWR Morb Mortal Wkly Rep 2018
67
14

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
11



SGLT inhibitor adjunct therapy in type 1 diabetes.
Rory J McCrimmon, Robert R Henry. Diabetologia 2018
38
23

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.
Yehuda Handelsman, Robert R Henry, Zachary T Bloomgarden, Sam Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Ele Ferrannini, Vivian A Fonseca, Alan J Garber, George Grunberger,[...]. Endocr Pract 2016
146
10

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.
Tadej Battelino, Thomas Danne, Richard M Bergenstal, Stephanie A Amiel, Roy Beck, Torben Biester, Emanuele Bosi, Bruce A Buckingham, William T Cefalu, Kelly L Close,[...]. Diabetes Care 2019
422
10


Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
847
8

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell,[...]. Diabetes Care 2015
115
8

Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2.
Chantal Mathieu, Paresh Dandona, Moshe Phillip, Tal Oron, Marcus Lind, Lars Hansen, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2019
20
40

Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases.
Susan J Bersoff-Matcha, Christine Chamberlain, Christian Cao, Cindy Kortepeter, William H Chong. Ann Intern Med 2019
68
11

The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis.
Jiao Chen, Fang Fan, J Y Wang, Yang Long, C L Gao, R C Stanton, Yong Xu. Sci Rep 2017
38
18

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
560
7


Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.
Jenny E Blau, Sri Harsha Tella, Simeon I Taylor, Kristina I Rother. Diabetes Metab Res Rev 2017
64
10

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
Fred Whitehouse, Davida F Kruger, Mark Fineman, Larry Shen, James A Ruggles, David G Maggs, Christian Weyer, Orville G Kolterman. Diabetes Care 2002
168
7

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger. Diabetes Care 2015
190
7

Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review.
Soulmaz Fazeli Farsani, Kimberly Brodovicz, Nima Soleymanlou, Jan Marquard, Erika Wissinger, Brett A Maiese. BMJ Open 2017
52
13

Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.
Roy W Beck, Richard M Bergenstal, Tonya D Riddlesworth, Craig Kollman, Zhaomian Li, Adam S Brown, Kelly L Close. Diabetes Care 2019
149
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.